News

Article

Lonza to Manufacture TxCell Product

TxCell announces manufacturing agreement with Lonza for its HLA-A2 CAR-Treg cellular product.

TxCell SA announced on May 31, 2018 that Lonza Pharma & Biotech will manufacture TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.

TxCell finalized its CAR-Treg manufacturing process, and the transfer to Lonza started in February 2018, according to Lonza’s timeline. The companies report the transfer will be complete and clinical manufacturing is expected to start by the first quarter of 2019. Accordingly, TxCell now expects to file its first CTA with TX200 in the first part of 2019.

Lonza will manufacture clinical batches of TxCell’s HLA-A2 CAR-Treg cellular product from its production site in Geleen, The Netherlands, and the final product can be shipped in a frozen state to clinical sites in Europe and the United States. TxCell has demonstrated that the drug product could be both frozen and thawed with no change in cellular phenotype and function, the companies report in the press statement.

Source: Lonza Pharma & Biotech

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content